Artiva Biotherapeutics (ARTV) Income from Continuing Operations (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Income from Continuing Operations of 35198000.0 for Q1 2026, up 4.46% year-over-year from 33695289.42 in Q1 2025, and down 66.17% quarter-over-quarter from 21182000.0 in Q4 2025.
Artiva Biotherapeutics (ARTV) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Income from Continuing Operations for 4 consecutive years, with 35198000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 4.46% year-over-year to 35198000.0; the TTM figure through Mar 2026 stood at 116492000.0 (up 4.44% YoY), while the FY2025 annual figure was 87730000.0, down 41.86% from the prior year.
- Income from Continuing Operations retreated to 35198000.0 in Q1 2026 per ARTV's latest filing, from 21182000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11229000.0 in Q3 2023 and bottomed at 36841000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 21993333.33 across 4 years, with a median of 23286000.0 in 2024.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 400.97% — and 2025, when it soared 30.87%.
- Artiva Biotherapeutics' Income from Continuing Operations stood at 11601000.0 in 2023, then tumbled by 100.05% to 23208000.0 in 2024, then gained by 8.73% to 21182000.0 in 2025, then tumbled by 66.17% to 35198000.0 in 2026.
- Business Quant data shows ARTV's Income from Continuing Operations at 35198000.0 in Q1 2026, 21182000.0 in Q4 2025, and 23364000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Artiva Biotherapeutics | 451.28 Mn | 451.28 Mn | - | -36.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.09 Mn |
| Mar 31, 2026 | -35.20 Mn |
| Dec 31, 2025 | -21.18 Mn |
| Sep 30, 2025 | -23.36 Mn |
| Jun 30, 2025 | -36.75 Mn |
| Mar 31, 2025 | -36.84 Mn |
| Dec 31, 2024 | -23.21 Mn |
| Sep 30, 2024 | -33.80 Mn |
| Jun 30, 2024 | -28.05 Mn |
| Mar 31, 2024 | -13.84 Mn |
| Dec 31, 2023 | -11.60 Mn |
| Sep 30, 2023 | 11.23 Mn |
| Jun 30, 2023 | -11.32 Mn |